Search results
Author(s):
Rajalakshmi Santhanakrishnan
Added:
3 years ago
Heart failure (HF) is a major health problem and about 6 million adults are affected in the US alone, at a cost of approximately $20 billion per year.1 Despite the availability of new treatment strategies, the incidence, number of hospitalizations and mortality associated with HF remains a big health burden.1 In addition to increasing age, the factors that contribute to poor prognosis for people…
View more
Author(s):
Robert Mentz
Added:
7 months ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID study (NCT03037931).
HEART-FID(American Regent, Inc.) aimed to determine the safety and efficacy of iron therapy using intravenous (IV) ferric carboxymaltose (FCM) as compared to a placebo in the treatment of patients with heart…
View more
Author(s):
Paul Kalra
Added:
1 year ago
Iron deficiency is common in heart failure, particularly in hospitalised patients and may exacerbate symptoms and increase the risk of hospitalisation and premature mortality. Although previous studies have shown that intravenous iron provides improvement in exercise capacity and reduces hospitalisation in patients with HF and iron deficiency, longer term efficacy and safety data has been lacking…
View more
Author(s):
Aarti Asnani
,
Randall T Peterson
Added:
3 years ago
Survival rates among patients diagnosed with cancer have improved dramatically over the past few decades. In 2016, there were an estimated 16 million cancer survivors in the United States, a number expected to increase to 20 million over the subsequent decade.1 One-third of these patients will survive at least 5 years after their initial cancer diagnosis, largely due to cancer therapies that are…
View more
Paul Kalra
Job title: Professor
Author
View from the Thoraxcenter: ESC 23 Wrap Up
Video Series
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Stay updated on the AHA 22 late-breaking data!
In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions.
What are the key take-aways from AHA 22? What are the most promising findings? How should we understand…
View more
Author(s):
Rebecca S Steinberg
,
Weston Dicken
,
Alexis Cutchins
Added:
6 months ago
Author(s):
Yugo Yamashita
Added:
7 months ago
What's hot at the European Society of Cardiology (ESC) Congress 2023?
Browse our curated coverage of the latest updates in cardiology from Amsterdam.
Watch ourView From the Thoraxcenterseries for a concise line up of the most awaited trials fromProf Nicolas Van MieghemandDr Joost Daemen.
For a deeper dive into key clinical trial data and its applicability, host,Dr Harriette Van…
View more
Author(s):
Marc Sirol
Added:
3 years ago
Atherosclerosis and its thrombotic complications are the first cause of mortality and morbidity in industrialized countries. Furthermore, despite pharmacological intervention and lifestyle changes, cardiovascular disease (CVD) continues to be the principal cause of death in the US. Despite great advances in the understanding of the initiation and progression of atherosclerosis and its risk…
View more